Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin

Pancreas

Volumn 40, Issue 6, 2011, Pages 855-860

  Kim, Young Seok ^a   Oh, Seung Hoon ^b   Park, Ki Soo ^a   No, Heesung ^b   Oh, Bae Jun ^a   Kim, Soo Kyoung ^b   Jung, Hye Seung ^c   Kim, Jae Hyeon ^a,b   Lee, Myung Shik ^a,b   Lee, Moon Kyu ^a,b   Kim, Kwang Won ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

DPP 4 inhibitor; GLP 1; islet; islet transplantation; pancreatectomy

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; SITAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; GLYCEMIC CONTROL; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; PANCREATECTOMY; PYRAZINES; TRIAZOLES;

EID: 80051552000     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318214832d     Document Type: Article

References (30)

1. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695-1704. (Pubitemid 44324122)
2. Butler AE, Janson J, Bonner-Weir S, et al. beta-Cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110. (Pubitemid 36042113)
3. Kim KW. Islet transplantation: A realistic alternative for the treatment of insulin deficient diabetes mellitus. Diabetes Res Clin Pract. 2004;66(suppl 1):S11YS17.
4. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69-75. (Pubitemid 28304880)
5. Dresler CM, Fortner JG, McDermott K, et al. Metabolic consequences of (regional) total pancreatectomy. Ann Surg. 1991;214:131-140.
6. Berney T, Rudisuhli T, Oberholzer J, et al. Long-term metabolic results after pancreatic resection for severe chronic pancreatitis. Arch Surg. 2000;135:1106-1111.
7. Sutherland DE, Gruessner AC, Carlson AM, et al. Islet autotransplant outcomes after total pancreatectomy: A contrast to islet allograft outcomes. Transplantation. 2008;86:1799-1802.
8. Blondet JJ, Carlson AM, Kobayashi T, et al. The role of total pancreatectomy and islet autotransplantation for chronic pancreatitis. Surg Clin North Am. 2007;87:1477Y1501, x.
9. Lee BW, Jee JH, Heo JS, et al. The favorable outcome of human islet transplantation in Korea: Experiences of 10 autologous transplantations. Transplantation. 2005;79:1568-1574.
10. Hamamoto Y, Tsuura Y, Fujimoto S, et al. Recovery of function and mass of endogenous beta-cells in streptozotocin-induced diabetic rats treated with islet transplantation. Biochem Biophys Res Commun. 2001;287:104-109. (Pubitemid 32912469)
11. Jung HS, Ahn YR, Oh SH, et al. Enhancement of beta-cell regeneration by islet transplantation after partial pancreatectomy in mice. Transplantation. 2009;88:354-359.
12. Thorens B, Waeber G. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM. Diabetes. 1993;42:1219-1225. (Pubitemid 23259839)
13. Perfetti R, Zhou J, Doyle ME, et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141:4600-4605. (Pubitemid 32055138)
14. De Leon DD, Deng S, Madani R, et al. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes. 2003;52:365-371. (Pubitemid 36173191)
15. De Meester I, Korom S, Van Damme J, et al. CD26, let it cut or cut it down. Immunol Today. 1999;20:367Y375.
16. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270-2276. (Pubitemid 30395416)
17. Kim SJ, Nian C, Doudet DJ, et al. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin- induced diabetic mice. Diabetes. 2008;57:1331-1339.
18. Kim D, Wang L, Beconi M, et al. (2R)-4-Oxo-4-[3-(trifluoromethyl)- 5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5- trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141-151. (Pubitemid 40105255)
19. Chae HY, Lee BW, Oh SH, et al. Effective glycemic control achieved by transplanting non-viral cationic liposome-mediated VEGF-transfected islets in streptozotocin-induced diabetic mice. Exp Mol Med. 2005;37:513-523.
20. Szot GL, Lee MR, Tavakol MM, et al. Successful clinical islet isolation using a GMP-manufactured collagenase and neutral protease. Transplantation. 2009;88:753-756.
21. Huang X, Moore DJ, Ketchum RJ, et al. Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation. Endocr Rev. 2008;29:603-630.
22. Woods EJ, Walsh CM, Sidner RA, et al. Improved in vitro function of islets using small intestinal submucosa. Transplant Proc. 2004;36:1175-1177. (Pubitemid 38766313)
23. Luo L, Badiavas E, Luo JZ, et al. Allogeneic bone marrow supports human islet beta cell survival and function over six months. Biochem Biophys Res Commun. 2007;361:859-864. (Pubitemid 47259018)
24. Lugari R, Dell'Anna C, Ugolotti D, et al. Effect of nutrient ingestion on glucagon-like peptide 1 (7Y36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res. 2000;32:424-428.
25. Tourrel C, Bailbe D, Meile MJ, et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001;50:1562-1570. (Pubitemid 33639596)
26. Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology. 2005;146:2069-2076. (Pubitemid 40396918)
27. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: Interactions with metformin. Diabetes. 2009;58:1604-1615.
28. Gradwohl G, Dierich A, LeMeur M, et al. neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci U S A. 2000;97:1607Y1611.
29. Lee CS, De Leon DD, Kaestner KH, et al. Regeneration of pancreatic islets after partial pancreatectomy in mice does not involve the reactivation of neurogenin-3. Diabetes. 2006;55:269-272. (Pubitemid 43343252)
30. Yue F, Cui L, Johkura K, et al. Glucagon-like peptide-1 differentiation of primate embryonic stem cells into insulin-producing cells. Tissue Eng. 2006;12:2105-2116. (Pubitemid 44734970)